Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Background Limited real-world data are available regarding the outcome of patients treated
with inappropriate dose of nonvitamin-K antagonist oral anticoagulants (NOACs). Objective …

Anticoagulation with direct-acting oral anticoagulants (DOACs) is recommended over
warfarin for stroke prevention in patients with atrial fibrillation (AF). The efficacy of DOACs …

Summary Background Direct oral anticoagulants (DOACs) are effective and safe alternatives
to warfarin for stroke prophylaxis for atrial fibrillation (AF). Whether this extends to patients at …

Background Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main
cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this …

Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …

Sex and gender differences have been reported in atrial fibrillation (AF), especially in
relation to differences in thromboembolic and bleeding risks. More recently …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

The development of nonvitamin K antagonist oral anticoagulants (NOACs) has been a major
advance in therapy for patients requiring oral anticoagulation, particularly for long-term …